Articles

A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis

Beijing Pediatric Research Institute & Children Hospital, Capital Medical Univ, Beijing, China;
Dept of Hematology Oncology, Beijing Children Hospital, Capital Medical University, Beijing, China;
Dept of Hematology Oncology, Beijing Children Hospital, Capital Medical University, Beijing, China;
Dept of Hematology Oncology, Beijing Children Hospital, Capital Medical University, Beijing, China;
Dept of Hematology Oncology, Beijing Children's Hospital, Capital Medical University, Beijing, China
Dept of Hematology Oncology, Beijing Children's Hospital, Capital Medical University, Beijing, China
Dept of Hematology Oncology, Beijing Children's Hospital, Capital Medical University, Beijing, China
Beijing Pediatric Research Institute & Children Hospital, Capital Medical Univ, Beijing, China;
Beijing Pediatric Research Institute & Children Hospital, Capital Medical Univ, Beijing, China;
Dept of Hematology Oncology, Beijing Children Hospital, Capital Medical University, Beijing, China;
Dept of Hematology Oncology, Beijing Children Hospital, Capital Medical University, Beijing, China;
Beijing Pediatric Research Institute & Children Hospital, Capital Medical Univ, Beijing, China;
Dept of Hematology Oncology, Beijing Children Hospital, Capital Medical University, Beijing, China;
Haematologica Early view Jul 30, 2020 https://doi.org/10.3324/haematol.2020.253781